| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $682K | +82.8% |
| Cost of Revenue | $615K | +135.6% |
| Gross Profit | $67K | -40.2% |
| R&D Expense | $20.5M | +80.9% |
| SG&A Expense | $27.2M | +111.0% |
| Operating Income | -$51.1M | -96.9% |
| Interest Expense | $65K | -97.4% |
| Pre-tax Income | -$18.7M | +72.8% |
| Net Income | -$18.7M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $737.9M | +834.7% |
| Short-term Investments | $379.4M | — |
| Accounts Receivable | $519K | +1822.2% |
| Inventory | $352K | +1855.6% |
| Current Assets | $1.13B | +1332.4% |
| Total Assets | $1.62B | +954.3% |
| Current Liabilities | $11.1M | +142.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$30.3M | -86.9% |
| Capital Expenditures | $6.7M | +10.8% |
| Investing Cash Flow | -$788.3M | — |
| Financing Cash Flow | $1.48B | +1390.4% |
| Free Cash Flow | -$37.0M | -66.2% |
| +72.8% |
| EPS (Basic) | -$0.11 | +84.9% |
| EPS (Diluted) | -$0.11 | +84.9% |
| Total Liabilities |
| $20.7M |
| -55.4% |
| Stockholders' Equity | $1.60B | +1389.7% |